{"url_path":"/sec/ints/8-k/2026-06-16/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1567264/0001567264-26-000049-index.html","accession_number":"0001567264-26-000049","cik":"0001567264","ticker":"INTS","issuer_name":"INTENSITY THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1567264/0001567264-26-000049-index.html","primary_entity_key":"0001567264","primary_entity_name":"INTENSITY THERAPEUTICS, INC."},"word_count":392,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 16, 2026, Intensity Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting\") via live webcast. At the Annual Meeting, 1,079,494 shares of common stock, or approximately 40.74% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person, representing a quorum.\n\nAt the Annual Meeting, the stockholders of the Company voted as set forth below on five proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2026. The final voting results for each matter submitted to a vote of the Company’s stockholders are as follows:\n\nProposal 1. Election of Directors.\n\nThe election of two Class III directors, to hold office until the 2029 annual meeting of stockholders or until their respective successors are elected and qualified.\n\nNomineeForWithheldBroker Non-Votes\n\nDr. Emer Leahy416,61319,465643,416\n\nLewis H. Bender422,14913,929643,416\n\nProposal 2. Ratification of Selection of Independent Registered Public Accounting Firm.\n\nThe ratification of the selection by the audit committee of the board of directors of EisnerAmper LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.\n\nForAgainstAbstain\n\n1,024,9714,85249,671\n\nProposal 3. Approval of Amendment to 2021 Stock Incentive Plan.\n\nThe Company’s stockholders approved an amendment to the Company’s 2021 Stock Incentive Plan (the “Plan”) to increase the number of shares of common stock available for sale under the Plan by 150,000.\n\nForAgainstAbstainBroker Non-Votes\n\n363,56369,2523,263643,416\n\nProposal 4. Approval of Amendment to 2024 Employee Stock Purchase Plan.\n\nThe Company’s stockholders approved an amendment to the Company’s 2024 Employee Stock Purchase Plan (the “ESPP”) to increase the number of shares of common stock available for sale under the ESPP by 25,000.\n\nForAgainstAbstainBroker Non-Votes\n\n407,40425,3503,324643,416\n\nProposal 5. Approval of any Postponement or Adjournment of 2026 Annual Meeting, If Necessary.\n\nThe Company’s Stockholders approved an adjournment of the Annual Meeting, if necessary, to solicit additional proxies in favor of proposals 1, 2, 3 and 4.\n\nForAgainstAbstain\n\n939,304126,81413,376\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: June 16, 2026\n\nIntensity Therapeutics, Inc.\n\nBy:/s/ Lewis H. Bender\n\nName: Lewis H. Bender\n\nTitle:Chief Executive Officer"}